Recent Updates
Recently added Catalysts
MNKD Positive Sentiment

MannKind to Participate in Upcoming Investor Conferences

Key Takeaway: MannKind Corporation will participate in two upcoming investor conferences in Miami. CEO Michael Castagna and CFO Chris Prentiss will engage in fireside chats and one-on-one meetings with investors. The conferences are scheduled for March 10 and March 11, 2026, and will be accessible via live audio webcasts on MannKind's website.
Price reaction · baseline $2.925 (2026-03-03 close) · hit pre-market · 2 other MNKD headline(s) in the window, move may be shared
day 0 close
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • MannKind is actively engaging with investors through conferences.
  • Participation in high-profile healthcare conferences enhances visibility.
  • CEO and CFO will directly interact with investors, fostering transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+93%
120-day peak, hindsight
Typical move
5.2%
average across 10 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
Technosphere Insulin
Phase 1 · Healthy Volunteers

Full Press Release Details

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) --MannKind Corporation (Nasdaq: MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind’s Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Chris Prentiss will participate in fireside chats and in 1x1 meetings with investors.

Leerink Partners 2026 Global Healthcare Conference in MiamiTuesday, March 10, 3:40 p.m. ET

Barclays 28thAnnual Global Healthcare Conference in MiamiWednesday, March 11, 1:00 p.m. ET

Links to the live audio webcast of the sessions will be available on MannKind Corporation’s website at:https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.
About MannKindMannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
Learn more at mannkindcorp.com.

Frequently Asked Questions

When will MannKind participate in the investor conferences?

MannKind will participate in investor conferences on March 10 and March 11, 2026.

Who will represent MannKind at the conferences?

CEO Michael Castagna and CFO Chris Prentiss will represent MannKind.

How can I access the conference sessions?

The sessions will be available via live audio webcasts on MannKind's website.

What is MannKind's focus as a biopharmaceutical company?

MannKind focuses on chronic disease care, particularly in cardiometabolic and orphan lung diseases.

Last updated: Mar 4, 2026